(VIANEWS) – Shares of ERYTECH PHARMA (CAC 40: ERYP.PA) rose by a staggering 22.7% in 10 sessions from €0.81 to €1.00 at 11:52 EST on Friday, following the last session’s downward trend. CAC 40 is rising 0.87% to €7,446.30, following the last session’s upward trend.
ERYTECH PHARMA’s last close was €1.02, 31.3% below its 52-week high of €1.48.
About ERYTECH PHARMA
ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, ERYTECH PHARMA has a trailing twelve months EPS of €-0.01.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.98%.
Yearly Top and Bottom Value
ERYTECH PHARMA’s stock is valued at €1.00 at 11:52 EST, way below its 52-week high of €1.48 and way above its 52-week low of €0.29.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ERYTECH PHARMA’s stock is considered to be oversold (<=20).
Earnings Before Interest, Taxes, Depreciation, and Amortization
ERYTECH PHARMA’s EBITDA is -12.58.
More news about ERYTECH PHARMA (ERYP.PA).
